Leveraging Open-Source Large Language Models to Identify Undiagnosed Patients with Rare Genetic Aortopathies

preprint OA: closed CC-BY-NC-ND-4.0
📄 Open PDF Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-04 · read from full text

The paper develops and validates an open-source, LLM-enabled genetic testing recommendation pipeline for rare genetic aortopathies, using retrieval-augmented generation over curated aortopathy-related knowledge bases to interpret narrative clinical notes and flag patients likely to benefit from genetic testing. It was evaluated on 22,510 Penn Medicine BioBank progress notes from 500 individuals (250 genetically confirmed cases and 250 controls), where the system categorized 425 of 499 patients and achieved a patient-level recommendation accuracy of 0.834 with precision 0.835, sensitivity 0.831, specificity 0.836, and F1/F3 around 0.833/0.832. A key caveat noted is that one case required additional clinician evaluation due to incomplete information, reflecting limitations from missing or insufficient note content. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

ABSTRACT Rare genetic aortopathies are frequently undiagnosed due to phenotypic heterogeneity, and delayed diagnosis can lead to fatal cardiac outcomes. While genetic testing can enable early proactive interventions, it relies on primary care physicians to recognize a genetic basis for symptoms and then refer patients to clinical genetics. Broad-scale screening methods are needed to identify cases that do not fit an obvious diagnostic pattern. Clinical notes, rich in narrative details, may support the automated flagging of patients for genetic testing. Given the strength of Large Language Models (LLMs) in processing unstructured text, we developed an open-source LLM-enabled genetic testing recommendation pipeline, which leverages retrieval augmented generation (RAG) on curated genetic aortopathy-related corpora to utilize relevant clinical knowledge for identifying patients likely to benefit from genetic testing. The pipeline was validated using 22,510 patient progress notes from 500 individuals (250 cases, 250 controls) in the Penn Medicine BioBank, and successfully categorized 425 out of 499 patients, with one case requiring further clinician evaluation due to incomplete information. The pipeline achieved a patient-level recommendation accuracy of 0.852, precision of 0.889, sensitivity of 0.803, F1-score of 0.844, and F3-score of 0.811. Our LLM-enabled workflow that integrates RAG showed strong performance in recommending genetic testing for patients with rare genetic aortopathies, demonstrating its potential to support undiagnosed patient identification from free-text clinical notes, thereby automating early disease identification and improving patient outcomes.
Full text 4,253 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Rare genetic aortopathies are frequently undiagnosed due to phenotypic heterogeneity, and delayed diagnosis can lead to fatal cardiac outcomes. While genetic testing can enable early proactive interventions, it relies on primary care physicians to recognize a genetic basis for symptoms and then refer patients to clinical genetics. Broad-scale screening methods are needed to identify cases that do not fit an obvious diagnostic pattern. Clinical notes, rich in narrative details, may support the automated flagging of patients for genetic testing. Given the strength of Large Language Models (LLMs) in processing unstructured text, we developed an open-source LLM-enabled genetic testing recommendation pipeline, which leverages retrieval augmented generation (RAG) on curated genetic aortopathy-related corpora to utilize relevant clinical knowledge for identifying patients likely to benefit from genetic testing. The pipeline was validated using 22,510 patient progress notes from 500 individuals (250 cases, 250 controls) in the Penn Medicine BioBank, and successfully categorized 425 out of 499 patients, with one case requiring further clinician evaluation due to incomplete information. The pipeline achieved a patient-level recommendation accuracy of 0.834, precision of 0.835, sensitivity of 0.831, specificity of 0.836, F1-score of 0.833, and F3-score of 0.832. Our LLM-enabled workflow integrating RAG showed strong performance in recommending genetic testing for patients with rare genetic aortopathies. These findings illustrate the feasibility of using open-source LLMs to support identification of patients who may benefit from genetic testing based on free-text clinical notes, providing a potential decision-support tool to assist clinicians in earlier recognition of rare genetic disease risks. Competing Interest Statement The authors have declared no competing interest. Funding Statement This research uses resources of the Argonne Leadership Computing Facility, a U.S. Department of Energy (DOE) Office of Science user facility at Argonne National Laboratory and is based on research supported by the U.S. DOE Office of Science-Advanced Scientific Computing Research Program, under Contract No. DE-AC02-06CH11357. This research also utilizes computing resources provided by the National Artificial Intelligence Research Resource (NAIRR) Pilot, supported by award NAIRR240008. This study was also supported by Genomic Medicine T32 Training Grant 5T32HG009495-08. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The IRB of University of Pennsylvania have given ethical approve for this work under protocol number 856828. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Footnotes ↵+ madduri{at}anl.gov, Anurag.Verma{at}pennmedicine.upenn.edu

Method

details are updated for clarity (Patient data, Knowledgebase curation). Additional analyses and corresponding figures are added (new: 1C, 1D) producing new results (updated: 1A, 1B). Figures 4A, 4B, 4F are updated for clarity. Discussion is updated providing relevant context for new results.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-22T02:00:06.705733+00:00
License: CC-BY-NC-ND-4.0